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ABSTRACT
Cancer death is a leading cause of global mortality. An estimated 14.1 million new 
cancer cases and 8.2 million cancer deaths occurred worldwide in 2012 alone. Cancer 
stem cells (CSCs) within tumors are essential for tumor metastasis and reoccurrence, 
the key factors of cancer lethality. Here we report that 4EGI-1, an inhibitor of the 
interaction between translation initiation factors eIF4E1 and eIF4G1 effectively 
inhibits breast CSCs through selectively reducing translation persistent in breast 
CSCs. Translation initiation factor eIF4E1 is significantly enhanced in breast CSCs in 
comparison to non-CSC breast cancer cells. 4EGI-1 presents increased cytotoxicity 
to breast CSCs compared to non-CSC breast cancer cells. 4EGI-1 promotes breast 
CSC differentiation and represses breast CSC induced tube-like structure formation 
of human umbilical vein endothelial cells (HUVECs). 4EGI-1 isomers suppress breast 
CSC tumorangiogenesis and tumor growth in vivo. In addition, 4EGI-1 decreases 
proliferation in and induces apoptosis into breast CSC tumor cells. Furthermore, 4EGI-
1 selectively inhibits translation of mRNAs encoding NANOG, OCT4, CXCR4, c-MYC 
and VEGF in breast CSC tumors. Our study demonstrated that 4EGI-1 targets breast 
CSCs through selective inhibition of translation critical for breast CSCs, suggesting 
that selective translation initiation interference might be an avenue targeting CSCs 
within tumors. 
INTRODUCTION
Cancer is a leading cause of mortality worldwide. 
Global cancer burden increased to 14.1 million new cases 
and 8.2 million cancer deaths in 2012 from 12.7 million 
and 7.6 million respectively, in 2008. Cancer metastasis 
and reoccurrence are the major resources of cancer 
lethality. Cancer stem cells (CSCs) form a subpopulation 
of cells within tumors and are essential for tumor 
dissemination and relapse[1]. The acquired properties 
that make CSCs adaptive to micro-environmental 
stresses and enhanced resistance to chemo-/radiation-
therapy, present a challenge for targeting CSCs within 
tumors[2-4]. Heterogenetic CSCs are believed to acquire 
diverse adaptive changes in genetic, epigenetic, signal 
transduction, metabolic, transcriptional and translational 
levels[5, 6]. Translation is essential for all aspects of tumor 
evolution, including tumorigenesis, tumorangiogenesis, 
tumor growth, metastasis, CSC heterogeneity, and drug 
resistance[7, 8]. Protein synthesis is central for CSCs 
self-renewal, maintenance, differentiation, growth and 
dissemination. 
Translation generally initiates with the recruitment 
of eIF4F to the 5’- m7GpppN cap of messenger RNA 
(mRNA)[9, 10]. eIF4F is a complex composed of the 
cap-binding protein eIF4E1, scaffold protein eIF4G1 and 
RNA helicase eIF4A. The eIF4E1/eIF4G1 interaction 
is necessary for eIF4F assembly[10-12]. The mRNAs 
encoding proteins important for cell proliferation and 
growth frequently harbor secondary structure and/or 
long 5’-UTR, or other regulatory elements. Translation 
of mRNAs with structured and/or long 5’-UTR is highly 
eIF4E1 dependent[13, 14]. Consistently, enhanced 
eIF4E1 levels and/or activities have been demonstrated 
in a number of cancers in clinical observations[15-18]. 
The human eIF4E family has three members of eIF4E1, Oncotarget 6029 www.impactjournals.com/oncotarget
eIF4E2 and eIF4E3. The eIF4E2-RBM4-HIF-2α complex 
can initiate translation but eIF4E2 does not bind to 
eIF4G1[19, 20]. eIF4E3 competes with eIF4E1 in binding 
cap and acts as a tumor suppressor[21]. Multiple proteins 
have been demonstrated to be enhanced in breast CSCs, 
such as the CSC markers NANOG and OCT4[22], the 
metastasis regulator CXCR4[23, 24], the epithelial–
mesenchymal transition (EMT)[25] regulator c-MYB[26], 
or the cell proliferation key factors c-MYC[27] and cyclin 
D1[28, 29]. 
Due to the central roles in cancer evolution, 
translation is targeted in anti-cancer drug development. 
Several agents targeting translation initiation have been 
developed[30, 31], including the small molecule 4EGI-
1[32]. 4EGI-1 binds eIF4E1, prevents recruitment of 
eIF4E1 to eIF4G1. The compound mimics the function 
of 4E-binding protein 1 (4E-BP1), which regulates 
eIF4E1-eIF4G interaction in a phosphorylation–dependent 
manner; however, 4EGI-1 does not displace 4E-BP1 from 
eIF4E1[32]. 4EGI-1 exhibits inhibitory effects in several 
cancer cell lines[33-35]. 
Recently, we have isolated and identified a small 
fast adhesion subpopulation (CD44high/CD24low)FA from 
HMLER human mammary epithelial cancer cells [1, 2] 
that show the typical properties of cancer stem cells and 
are referred to as breast cancer stem cells (CSCs)[36]. 
These breast CSCs showed enhanced drug resistance to 
the anti-cancer drugs actinomycin D and camptothecin 
(about 10-fold) compared to non-CSCs [36]. However, 
it is unknown whether 4EGI-1 inhibits breast CSCs and 
suppresses breast CSC tumor growth, and whether 4EGI-
1 interferes with translation selectively in breast CSCs is 
elusive. 
We investigated the effects of 4EGI-1 on breast 
CSCs of HMLER (CD44high/CD24low)FA cells in vitro 
and breast CSC tumorangiogenesis and tumor growth in 
xenografted tumor model in vivo. We found that eIF4E1 is 
significantly increased in breast CSCs comparing to non-
CSC breast cancer cells. 4EGI-1 selectively inhibits breast 
CSCs in comparison to non-CSC breast cancer cells. Both 
4EGI-1 isomers repress breast CSC tumorangiogenesis 
and tumor growth in mouse model. They inhibit cell 
proliferation and increase cell apoptosis in breast CSC 
tumors. 4EGI-1 selectively inhibits translation of mRNAs 
of NANOG, OCT4, CXCR4, c-MYB, c-MYC and cyclin D1 
in breast CSC tumors. These results suggest that 4EGI-1 
targets breast CSCs through selectively inhibits translation 
of mRNAs essential for breast CSCs.
RESULTS 
Translation initiation factor eIF4E1 is enhanced 
in breast CSCs
To investigate the underlying translational 
mechanisms  that  are  specifically  required  for  CSC 
character maintenance of breast CSCs (BCSCs), we 
compared the cellular protein abundances of multiple 
translation initiation factors by Western blot assays in 
breast CSCs HMLER (CD44high/CD24low)FA cells and 
multiple non-CSC breast cancer cells (non-BCSCs). We 
found that eIF4E1 (also named eIF4E), but not eIF4E2, 
eIF4G1, eIF1A, eIF2α, or eIF5, is significantly increased 
in BCSCs, in comparison to SKBR-3, MCF-7 and MDA-
MB-231 breast cancer cells and non-BCSCs of HMLER 
(CD44high/CD24low)SA cells (Fig.1A). eIF4E3 is hardly 
detectable in all these cancer cells. These results suggest 
that the activation of eIF4E-dependent translation is 
enhanced in these BCSCs. 
Selective inhibition of breast CSCs by 4EGI-1 
comparing to non-CSCs
4EGI-1 consists of two isomers: [E]- and [Z]-
4EGI-1. To evaluate the effects of 4EGI-1, we synthesized 
and  identified  an  inactive  analogue  4EGI-N(410E) 
(Fig.1B). We compared the inhibitory effects of 4EGI-
1 isomers on breast CSCs and multiple non-CSC breast 
cancer cells by ATP concentration based cell viability 
assays. We observed that the IC50 of 4EGI-1 is about 
30µM on SKBR-3, MCF-7 and MDA-MB-231 breast 
cancer cells, about 22µM on non-CSCs, and about 11µM 
Table 1: Cytotoxicity of 4EGI-1 isomers on breast CSCs and breast cancer cells.
BCSCs and breast cancer cells IC50 of [E]-4EGI-1(µM) IC50 of [Z]-4EGI-1(µM) 
SKBR-3 30±1.5 29±1.3
MCF-7 30±0.9 30±1.1
MDA-MB-231 32±1.2 30±1.4
Non-BCSCs of HMLER(CD44high/CD24low)SA 24±1.1 22±0.7
BCSCs of HMLER(CD44high/CD24low)FA 11±0.8 10±0.6
Note: IC50 means inhibitory concentration that leads to 50% cell viability decrease. Oncotarget 6030 www.impactjournals.com/oncotarget
([E]-)/10µM ([Z]-) on breast CSCs (Table 1). The above 
data indicate that 4EGI-1 presents increased cytotoxicity 
(>2-fold) to breast CSCs comparing to non-CSC breast 
cancer cells, which is in agreement with the significantly 
enhanced eIF4E1 in breast CSCs (Fig. 1A).
4EGI-1 promotes breast CSC differentiation
CSC maintenance and differentiation are important 
for CSC tumorigenesis and tumor evolution[37]. CD44high/
CD24low is one of the defining characteristics of these 
breast CSCs, whereas CD44low/CD24high represents the 
CSC-depleted population of these breast cancer cells. We 
treated the breast CSCs with 4EGI-1 isomers, an inactivate 
analogue 4EGI-N(410E) and vehicle with series of 
concentrations for three days followed by flow cytometry 
analyses with CD44 and CD24 antibodies. 4EGI-1 isomers 
significantly decreased the percentage of CD44high/CD24low 
population cells and increased the population of CD44low/
CD24high cells (Fig. 2A-2B). 4µM [E]- or [Z]-4EGI-1 
depleted most of breast CSCs. Importantly, inactive 
analogue 4EGI-N(410E) did not affect breast CSCs under 
the same conditions (Fig. 2A-2B). These results suggested 
that 4EGI-1 potently depletes breast CSCs and promotes 
Figure 1: Translation initiation factor eIF4E1 is enhanced in breast CSCs and structures of compounds. (a) Western 
blot analyses of translation initiation factor abundance in SKBR-3, MCF-7, MDA-MB-231 breast cancer cells, breast CSCs (BCSCs) of 
HMLER (CD44high/CD24low)FA cells and non-BCSCs of HMLER (CD44high/CD24low)SA breast cancer cells. β-actin was used as a loading 
control. (b) Structures of 4EGI-1 isomers ([E]- and [Z]-isomer) and inactive analogue 4EGI-N(410E). Arrow shows the double bonds. 
Figure 2: 4EGI-1 promotes breast CSC differentiation. (a) Representative fluorescence-activated cell sorting (FACS) images. 
CD44high/CD24low population cells and CD44low/CD24high population cells with DMSO, 4µM 4EGI-N(410E) , 4µM[E]-4EGI-1, or 4µM[Z]-
4EGI-1 treatment for three days were shown. Both 4EGI-1 isomers promote breast CSC differentiation. (b) Statistical analyses of 4EGI-1 
effects on CD44high/CD24low population cell percentage of breast CSCs. Average CD44high/CD24low percentages were shown (mean ± SD, 
t-test, two-tailed). *: p< 0.1; **: p< 0.05; ***: p< 0.01. Oncotarget 6031 www.impactjournals.com/oncotarget
breast CSC differentiation. 
4EGI-1 inhibits breast CSC induced HUVEC 
tube-like structure formation
 Angiogenesis is the process of new vessel generation 
and growth, which is important for tumor growth and 
metastasis[38]. CSCs produce multiple proangiogenic 
factors to stimulate tumor angiogenesis[39]. To examine 
whether 4EGI-1 inhibits proangiogenic factor protein 
synthesis in breast CSCs, we employed human umbilical 
vein endothelial cells (HUVECs). We pretreated breast 
CSCs with compounds at the indicated concentrations 
for 3 hours. Then, we embedded these breast CSCs in 
50% growth factor reduced Matrigel (mixed with 50% 
breast CSC medium MEGM) and planted HUVECs on 
the surface of these Matrigel mixtures with endothelial 
cell growth medium (EGM) (Fig. 3A). After incubation 
at 37oC for two days, breast CSCs pretreated with 
DMSO and inactivate analogue 4EGI-N(410E) grew into 
tumorspheres, while those treated with 4EGI-1 isomers did 
not (Fig. 3B). HUVECs cultured on the surface of Matrigel 
mixture with DMSO pretreated breast CSCs formed tube-
like structures (33±2 tubes/HPF, high performance field, 
20×), and 32.6±2.58 tubes/HPF with 4EGI-N(410E) 
pretreated breast CSCs. In contrast, HUVECs only formed 
4.5±1 tubes/HPF and 4.1±0.7 tubes/HPF with 8µM [E]- 
and [Z]-isomer pretreated breast CSCs, respectively 
(Fig. 3C-D). Importantly, 4EGI-N(410E) did not affect 
HUVEC tube formation and HUVECs hardly form tubes 
on growth factor reduced Matrigel (Fig. 3D). These results 
demonstrated that 4EGI-1 inhibits proangiogenic factor 
production  in  breast  CSCs  and  significantly  represses 
breast CSC promoted HUVEC tube formation.
4EGI-1 suppresses breast CSC tumor growth and 
tumorangiogenesis
To investigate the effects of 4EGI-1 on breast CSC 
tumor growth in vivo, we employed xenografted tumor 
model in mouse. After the breast CSC tumor formation 
(tumor volume is about 75 mm3), we injected both 
Figure 3: 4EGI-1inhibits breast CSC induced HUVEC tube-like structure formation. (a) Diagram of HUVEC-breast CSC 
sandwich. Breast CSCs were embedded in 50% growth factor reduced Matrigel (mixed with 50% MEGM medium). Human umbilical 
vein endothelial cells (HUVECs) were planted on Matrigel mixture in endothelial growth medium (EGM). (b) Representative images of 
breast CSC mammospheres (top panels) or breast CSCs (bottom panels) in Matrigel mixture. Breast CSCs were pretreated with DMSO, 
8µM 4EGI-N(410E), 8µM[E]-4EGI-1, or 8µM[Z]-4EGI-1 for 1 day, followed by culturing in Matrigel mixture for three days. Images were 
taken at the third day in Matrigel mixture. Bar=10µm. (c) Representative images of HUVEC tube-like structures. HUVECs were cultured 
on Matrigel mixture containing 8µM compound pretreated breast CSCs for 24hr. Images were taken at 24hr. Breast CSCs (mammospheres) 
promote HUVEC tube formation, and 4EGI-1 inhibits this capacity of breast CSCs. (d) Statistical analyses of 4EGI-1 effects on 4EGI-1 
effects on breast CSC stimulation of HUVEC tube formation. “ˍ ˍ” means Matrigel mixture contains no breast CSCs. 50% growth factor 
reduced Matrigel does not lead to HUVEC tube formation. Average tube numbers per high performance field (20×) were shown (mean ± 
SD, t-test, two-tailed). **: p< 0.05; ***: p< 0.01. Oncotarget 6032 www.impactjournals.com/oncotarget
4EGI-1 isomers 75 mg/kg/day (5 mice for each group) 
by intraperitoneal injection (I.P.) for 30 days. Tumor 
volumes were measured every three days. At the 30th 
day, the average breast CSC tumor volume of vehicle 
treatment was 237.4±18.6 mm3, whereas the average 
breast CSC tumor volumes of [E]- and [Z]- isomer treated 
were 113.2±11.4 mm3 and 123.9±10.8 mm3, respectively 
(Fig. 4A). The average breast CSC tumor weights of 
vehicle, [E]-, [Z]- isomer treated were 0.0825±0.01145g, 
0.036±0.00618g, 0.038±0.0077g, respectively (Fig. 
4B). These data demonstrated that 4EGI-1 effectively 
suppressed breast CSC tumor growth in vivo. Then, we 
performed hematoxylin and eosin (H&E) staining and 
immunohistostaining with anti-mouse CD31 (vascular 
endothelial cell marker) antibodies with breast CSC 
tumor  sections.  4EGI-1  significantly  decreased  vessel 
numbers in breast CSC tumors (Fig. 4C), suggesting that 
4EGI-1 inhibits angiogenesis in breast CSC tumors in 
vivo. Next, we performed immunohistostaining to detect 
cell proliferation marker Ki-67 and cell apoptosis marker 
cleaved CASP3 (cCASP3) in these breast CSC tumor 
sections. 4EGI-1 decreased Ki-67 in most breast CSC 
tumor cells and increased cCASP3 in a few breast CSC 
tumor cells (Fig. 4D), suggesting that 4EGI-1 significantly 
Figure 4: 4EGI-1 suppresses breast CSC tumor growth and tumorangiogenesis in vivo. (a) The graph represents average 
tumor volumes of each group over time. The average tumor volume from DMSO treated group increased from 74.30±2.43 to 237.4± 
18.6mm3, whereas that from [E]-4EGI-1 treated group increased from 76.87±1.96 to 113.2±11.4 mm3, and that from [Z]-4EGI-1 increased 
from 75.01±1.75 to 123.9 ±10.8 mm3. Bar represents tumor volume mean ± SD (n=5 mice, t-test, p<0.001). (b) Average tumor weights of 
each group. The average tumor weight from DMSO treated group is 0.08524±0.01145g, whereas that from [E]-4EGI-1 treated group is 
0.036± 0.00618g and that from [Z]-4EGI-1 treated group is 0.038±0.0077g (mean ± SD, n=5, t-test). (c) Representative H&E staining (top 
panels) and immunohistostaining (bottom panels) images of anti-mouse CD31 antibody in tumor cross-sections. Left panel: Statistical data 
from immunohistostaining analyses expressed as average tumor vessel number per high performance field (HPF, 200×) with 12.2±1.92 
vessel/HPF in DMSO treated tumor group, 2.4±0.54 vessel/HPF in [E]-4EGI-1treated tumor group, and 3±0.7 vessel/HPF in [E]-4EGI-
1treated tumor group (mean ± SD, n=6, t-test). Arrows indicate vessels and microvessels. V: vessels; MV: microvessels. (d) Representative 
immunohistostaining images of tumor cross-sections with anti-Ki-67 and anti-cleaved Caspase 3 (cCASP3) antibodies. Arrows indicate 
signals of Ki-67 or cCASP3. Framed areas show the enlarged images of cCASP3 signals. (e) Representative immunohistostaining images 
of cross-sections with anti-cyclin D1 and anti-c-MYC antibodies. Arrows indicate signals of cyclin D1 or c-MYC. Oncotarget 6033 www.impactjournals.com/oncotarget
inhibits breast CSC proliferation and can induce apoptosis 
in breast CSCs in vivo. Furthermore, we found 4EGI-1 
strikingly decreased cell proliferation key regulators 
cyclin D1 and c-MYC in breast CSC tumor cells (Fig. 4E), 
indicating that 4EGI-1 inhibits translation essential for cell 
proliferation in breast CSCs.
4EGI-1 selectively inhibits translation that 
persists in CSC maintenance and dissemination 
To examine the 4EGI-1 effects on translation 
essential for CSC maintenance and dissemination, we 
performed Western blot with cellular proteins extracted 
from these breast CSC tumors. 4EGI-1 treated tumor cells 
presented decreased CSC pluripotency markers NANOG 
and OCT4, tumor metastasis regulator CXCR4, EMT 
mediator c-MYB and proangiogenic factor VEGF[40, 
41], but not translation initiation factors eIF1A or eIF5, 
comparing to vehicle treated breast CSC tumor cells in 
vivo (Fig. 5A). Previously, we reported that 4EGI-1 
inhibits translation of several oncogene mRNAs without 
affecting their transcription in multiple cancer cell lines 
at 24hr under normoxia and at 12hr under hypoxia 
conditions in vitro[16, 32]. These observations suggested 
that the indicated decreased protein levels in 4EGI-1 
treated BCSC tumors were primarily, if not all, caused 
by selective inhibition of translation of mRNAs encoding 
these proteins. Importantly, we found that 4EGI-1 isomers 
inhibit the eIF4E1-eIF4G1 interaction and increase 4E-
BP1 stability of binding to eIF4E1 in breast CSC tumor 
cells in vivo (Fig. 5B). These results demonstrated 
that 4EGI-1 selectively inhibits translation of mRNAs 
encoding proteins that persists in CSC maintenance, pro-
angiogenesis and metastasis. 
DISCUSSION
Cancer stem cells are critical for tumor metastasis 
and reoccurrence, which are the major resources of cancer-
related lethality. CSCs have acquired enhanced drug 
resistance. Here we found that small molecule 4EGI-1 
preferentially inhibits breast CSCs compared to non-CSC 
breast cancer cells in vitro and effectively suppresses 
breast CSC tumor growth and tumorangiogenesis in vivo. 
4EGI-1 promotes breast CSC differentiation, inhibits 
breast CSC tumorsphere growth and suppresses HUVEC 
tube formation. 4EGI-1 significantly inhibits breast CSC 
proliferation and can induce apoptosis in breast CSC tumor 
cells. Furthermore, we found that 4EGI-1 selectively 
inhibits translation of mRNAs encoding proteins that 
are enhanced in CSC maintenance, proliferation and 
metastasis, such as NANOG, OCT4, c-MYC, cyclin D1, 
CXCR4, VEGF and c-MYB, in breast CSC tumor cells. 
Our study suggests that selective translation initiation 
interference by 4EGI-1 inhibits breast CSC tumor growth 
and tumorangiogenesis (Fig. 5C).
Malignant cancer cells typically undergo extensive 
adaptive genetic, epigenetic and metabolic changes to 
support the heterogeneous malignant phenotypes, yet 
cell survival and proliferation may dependent on one 
or a subset of driver mutations[42, 43]. This continued 
dependence on the driver mutation is deferred to oncogene 
Figure 5: 4EGI-1 selectively inhibits translation in 
breast CSC tumors. (a) 4EGI-1 decreases NANOG, OCT4, 
CXCR4, c-MYB and VEGF, but not eIF1A or eIF5, in breast 
CSC tumors. Western blot assays of 4EGI-1 effects on translation 
in breast CSC tumors. Total proteins were extracted from 
tumor tissues. Western blot were performed three independent 
experiments with indicated antibodies. Tubulin was used as a 
loading control. (b) 4EGI-1 disrupts eIF4E1-eIF4G1 interaction 
and increases stability of 4E-BP1 binding to eIF4E1 in breast 
CSC tumors. Co-immunoprecipitation assays were performed 
using anti-eIF4E antibody or control IgG. “Input” represents 
10% of total protein used in immunoprecipitation. (c) Schematic 
diagram for enhanced eIF4E1 in breast CSCs, selective 
translation initiation interference by 4EGI-1 in breast CSCs, and 
inhibitory effects of 4EGI-1 on breast CSC tumorangiogenesis 
and tumor growth. 4EGI-1 binds to eIF4E1, inhibits eIF4E1-
eIF4G1 interaction, and increase 4E-BP1 binding to eIF4E1. 
4EGI-1 selectively inhibits translation essential for breast CSC 
maintenance, proliferation and metastasis, and suppresses breast 
CSC tumorangiogenesis and tumor growth.Oncotarget 6034 www.impactjournals.com/oncotarget
addiction[42]. Inhibition of the addictive oncoproteins can 
lead to therapeutic intervention, which is the basis for a 
considerable promise of current chemotherapy. However, 
the followed tumor reoccurrence, tumor metastasis and 
drug resistance suggest limits of using inhibitors targeting 
one or a few addictive oncoproteins. Although it is known 
that: 1) CSC quiescence decreases drug sensitivity; and 2) 
CSCs may never acquire addiction to the oncogene that 
drives disease development, the mechanisms of enhanced 
drug resistance of CSCs are elusive[4]. Despite of the 
extreme complexity of increased drug resistance of 
CSCs[45], it is possible to target the CSC-specific adaptive 
translational mechanisms that constantly produce proteins 
to support CSC maintenance, self-renewal and metastasis. 
Here, we found that translation initiation factor eIF4E1, 
but  not  eIF4E2,  eIF4G1,  eIF1A,  eIF2α,  or  eIF5,  is 
significantly enhanced in breast CSCs in comparison to 
non-CSC breast cancer cells. We show that the eIF4E1-
eIF4G1 interaction inhibitor 4EGI-1 preferentially 
inhibits breast CSCs compared to non-CSC breast cancer 
cells, effectively suppresses breast CSC tumor growth, 
selectively inhibiting translation of mRNAs encoding 
NANOG, OCT4, CXCR4, c-MYC, cyclin D1, c-MYB 
and VEGF, but not eIF1A or eIF5. CXCR4 and c-MYC 
are addictive oncoproteins of many malignant tumors. 
Therefore, 4EGI-1 both inhibits addictive oncoproteins 
and interferes with the CSC adaptive protein synthesis 
machinery in breast CSCs. These results not only 
demonstrate that 4EGI-1 is a potential candidate for CSC-
targeted cancer therapy, but more importantly, suggest that 
the eIF4E1-eIF4G1 interaction is an available target for 
the selective inhibition of CSCs. 
It has been demonstrated that translation of mRNAs 
encoding proteins important for cell proliferation and 
survival is highly eIF4E1 dependent [15, 44]. Here 
we show that 4EGI-1 selectively inhibits translation 
essential for breast CSCs, including NANOG,  OCT4, 
CXCR4, c-MYC, c-MYB and VEGF. Data shown here 
and elsewhere[32] have consistently evidenced that 
4EGI-1 performs selective translation interference in 
breast CSCs and multiple cancer cell lines. Here we show 
that 4EGI-1 increases cytotoxicity to breast CSCs that 
exhibit enhanced drug resistance to anti-cancer drugs of 
Actinomycin D and Camptothecin (about 10-fold). This 
suggests that 4EGI-1 can selectively target breast CSCs. 
The intraperitoneal injection and suppression of breast 
CSC tumor growth, and the low side effects on mice (data 
not shown) in this study reflect the selective breast CSC 
inhibition by 4EGI-1. In short, 4EGI-1 exhibits capacities 
of both selective translation initiation interference and 
selective breast CSC inhibition.
CSC maintenance facilitates tumorigenesis and 
tumor reoccurrence[22], and CSC quiescence decreases 
sensitivity to inhibitors[45, 46]. Furthermore, CSC 
depletion reduces CSC tumorigenesis capacity. We 
found that 4EGI-1 inhibits breast CSC maintenance 
and promotes breast CSC differentiation with decreased 
CD44high/CD24low population and increased CD44low/
CD24high population cells. Furthermore, 4EGI-1 decreased 
CSC markers of NANOG and OCT4 in breast CSC 
tumors, which associate with hypoxia (low oxygen) within 
solid tumors. These consistent results demonstrate that 
4EGI-1 effectively promotes breast CSC differentiation 
by selectively impairing translation required for CSC 
maintenance.
Cancer cells have acquired capacities of 
uncontrolled proliferation and apoptosis evasion[47]. 
We  found  that  4EGI-1  significantly  decreases  cell 
proliferation, and c-MYC and cyclin D1 protein levels in 
breast CSC tumors. 4EGI-1 can induce apoptosis in CSCs 
within breast CSC tumors. These observations evidenced 
that selective translation initiation interference may be 
an avenue to effectively suppress proliferation in and 
induce apoptosis into CSCs. On the other hand, targeting 
CSC adaptive translation machinery may overcome: 
1) inherent resistance to drugs targeting one or a few 
oncoproteins, which is caused by CSC heterogeneity 
and/or compensation of diverse/redundant oncoproteins 
in a type of CSCs[41]; and 2) acquired resistance due to 
mutations after drug treatment[48, 49].
We present here the first small molecule activities 
against breast cancer stem cells through selective 
translation initiation interference. Selective inhibition of 
translation of mRNAs encoding proteins essential for CSC 
maintenance, self-renewal, proliferation, differentiation, 
and dissemination could be an avenue to restrict and 
inhibit CSC activities, including CSC tumorangiogenesis 
and tumor growth. Targeting selective translation initiation 
is expected to overcome resistance due to mutations 
acquired during drug treatment and the related inherent 
CSC heterogeneity. 
MATERIAL AND METHODS
Cells, antibodies, reagents and mice
HMLER cell line was kindly provided by 
Robert Weinberg (Whitehead Institute for Biomedical 
Research of Massachusetts Institute of Technology). 
HMLER(CD44high/ CD24low)FA cells were prepared as 
previously described[36]. MEGM and MEBM media, 
EGM media, and Human Umbilical Vein Endothelial Cells 
(HUVECs) were purchased from Lonza. The [E]- and 
[Z]-4EGI-1were either self-synthesized or ordered from 
Speed Chemical. 4EGI-N (410E) was self-synthesized. All 
compounds were dissolved in DMSO. NOD-SCID (strain 
name: NOD.CB17-Prkdcscid/J) mice were ordered from 
The Jackson Laboratory. Anti-Ki-67(SP6) antibody was 
ordered from Vector (#VP-RM04). Anti-cleaved CASP3 
(5A1E) antibody for immunostaining was ordered from Oncotarget 6035 www.impactjournals.com/oncotarget
Cell Signaling (#9664s). Anti-CD31 (mouse) antibody 
was ordered from Dako (#N1596). Anti-c-Myc (N-term) 
antibody used for immunostaining was ordered from 
Epitomics (#1472-1). Anti-cyclin D1 antibody used for 
immunostaining was ordered from Neomarkers (#RM-
9104-S). Anti-eIF4E1, anti-eIF4G1, anti-4E-BP1, and 
anti-β-actin antibodies were ordered from Cell Signaling. 
Cancer cell lines of SKBR-3, MCF-7, MDA-MB-231 
were ordered from ATCC. Anti-c-MYC and anti-cyclin 
D1 antibodies were ordered from Cell Signaling. 
Western blot assay
Cellular protein extraction and Western blot assays 
were performed as previously described with RIPA buffer 
(50mM Tris-HCl pH 7.4, 150mM NaCl, 1% Triton-X100, 
0.1% SDS, 0.25% Na-deoxycholate, 1mM PMSF, 
1×Roche complete mini protease inhibitor cocktail). 
Immuno blots were performed with indicated antibodies. 
All Western blot experiments were performed three times.
Cell viability assay
1 × 104 breast CSCs HMLER (CD44high/CD24low)FA 
cells and other indicated breast cancer cells were treated 
with DMSO, or [E]-4EGI-1 or [Z]-4EGI-1 at series of 
concentrations for 24 hours. The cells were performed 
cell viability assays with CellTiter-Glo® luminescent 
cell viability assay kit (Promega) according to the 
manual description. Three independent experiments were 
performed. Average IC50 results were shown (mean ± SD, 
t-test, two-tailed). 
Fluorescence-activated cell sorting (FACS)
 Breast CSCs were treated with the indicated 
compounds at indicated concentrations for three days, 
followed by fluorescence-activated cell sorting (FACS) 
assay with FITC-conjugated anti-CD44 (Biosciences, 
G44-26) antibodies and PE-conjugated anti-CD24 
(Biosciences, ML15) antibodies. 
HUVEC tube-like structure formation
A  200μl  50%  growth  factor  reduced  Matrigel 
mixture (BD Medical, mixed with MEGM at ratio of 
1:1) was added to each well of 24-well plates followed 
by incubation at 37oC for 30 minutes. Breast CSCs 
were treated with DMSO, 4EGI-N(410E), [E] and [Z] 
at indicated concentrations for one day, and cultured on 
Matrigel mixture, and covered by another 150 μl Matrigel 
mixture followed by incubation at 37oC for 30 minutes. 
Then 0.3 ml MEGM was added to each well and the plates 
were incubated at 37oC, 5% CO2 for 3 days. Images of 
breast CSCs or tumorspheres were taken by Nikon camera. 
After aspiration of the MEGM medium, 4×104 HUVECs 
were cultured into each well together with 0.3 ml EGM 
medium followed by incubation at 37oC, 5% CO2 for 24 
hours. Images of HUVEC tube-like structure were taken 
by Nikon camera. The HUVEC tube-like structures in high 
performance fields (20×) were counted. The experiments 
were performed three independent times. 
Tumor xenografted assay
In the tumor xenografted assay, 1×105 breast 
CSCs were mixed with 100μl Matrigel/DMEM mixture 
(Matrigel: DMEM = 1:2) (BD Bioscience). Breast CSCs/
Matrigel/DMEM mixtures were injected into NOD/SCID 
female mice (the Jackson Laboratory) mammary glands by 
subcutaneous injection. After the tumor formation (about 
75 mm3 in volume, 5 mice/group), DMSO, or 75mg/kg 
[E]-4EGI-1, or 75mg/kg [Z]-4EGI-1 was injected into 
the mice by intraperitoneal injection daily for 30 days. 
Tumor volumes were measured every three days. At the 
30th day, mice were sacrificed and tumors were excised. 
Tumors weights were measured. Tumor tissue samples 
were used for immunohistostaining, Western blot and 
immunoprecipitation analyses. The mouse experiments 
were performed according to the policies of Harvard 
Medical Animal Committee.
Statistical analysis
Quantitative data were statistically analyzed (mean 
± SD, t-test,  two-tailed).  Statistical  significance  was 
determined by t-test. Significance was expressed as: *: p< 
0.1; **: p< 0.05; ***: p< 0.01, or with the p-value. P<0.05 
was considered significant[2].
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